

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 66730

Title: The tsunami of immunotherapy reaches mesothelioma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05258171

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Spain

Manuscript submission date: 2021-04-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-12 03:27

Reviewer performed review: 2021-04-20 03:06

Review time: 7 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this manuscript, Mielgo-Rubio et.al. reviewed the recent studies on the immunotherapy of mesothelioma. The authors focused on the results of two phase III clinical trials, which represent a major landmark in the treatment of MPM. The following needs to be addressed: 1. Please consider replacing all tables with a three-line tables, and improve Table 2 to make its content more clear. References should be included in the tables. 2. Please try to summarize the advantages of nivolumab and ipilimumab as a new first-line treatment strategy compared to previous regimens. Please try to merge it into a table. 3. This article introduces the therapeutic effect and adverse effects of doublet chemotherapy with cisplatin and pemetrexed on mesothelioma, as well as the effect of novel nivolumab and ipilimumab immunotherapy. However, the adverse effect of nivolumab and ipilimumab immunotherapy was not introduced. 4. In the treatment of malignant mesothelioma targeting PD-L1, nivolumab and ipilimumab had shown different results. In addition, how does the nivolumab and ipilimumab act as an inhibitor on the PD-1/PDL-1 pathway? Please try to explain these reasons.